An interventional study of tributyrin and Control in Healthy Overweight/Obese, sponsored by University of Aarhus. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by University of Aarhus · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Obesity by University of Aarhus — 5 open to participants now, 7 under way, none of them phase 3. Obesity · University of Aarhus.
Among the 40 studies in Obesity by University of Aarhus, this one is the 22nd largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2026, is one of 24 with no phase, and was the 40th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →5 of the 40 studies in Obesity by University of Aarhus are open now, in 1 country. Recruiting first, the newest first:
University of Aarhus · Sites in Denmark
Ages 55–70 · Healthy volunteers
University of Aarhus · Sites in Denmark
Ages 18+ · Healthy volunteers
University of Aarhus · Sites in Denmark
Ages 18–75 · Healthy volunteers
University of Aarhus · Sites in Denmark
Ages 7–14 · Healthy volunteers
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 30 across the 26 interventional studies, 67 across the 14 observational. Of the 30 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Aarhus is the lead sponsor of 1,303 studies on the registry; 190 are open to participants now.
2 of the studies in Obesity by University of Aarhus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07463495University of AarhusThe Metabolic Effects of Oral Tributyrin Administration | 2026-12 |
| NCT07359625University of AarhusEffects of Ketone Bodies on Insulin Sensitivity | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 40 studies in Obesity by University of Aarhus, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this double-blinded randomized clinical cross-over trial is to investigate the metabolic and appetite regulating effects of oral tributyrin (a butyrate pro-drug) administration vs placebo.
The main questions it aims to answer are:
A sample size calculation estimated a minimum of 10 participants. We expect to include 12 participants in this study. Tributyrin or placebo is ingested once or twice daily for 2x2 weeks, separated by a washout period of minimum 2 weeks. On trial day following each 2-week period we assess:
While at home, subjects will wear a sleep monitoring device for three consecutive nights and deliver fecal samples for analysis of short-chain fatty acid content and microbiota composition.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral ingestion of tributyrin
Dietary Supplement: tributyrin
Oral ingestion of placebo
Dietary Supplement: Control
Oral ingestion of tributyrin (liquid) once daily (20 g x 1) for 7 days, then twice daily (20 g x 2) for 7 days.
Oral ingestion of water (liquid) with added bitter substance once daily (20 ml x 1) for 7 days, then twice daily (20 ml x 2) for 7 days
Postprandial glucose
iAUC of plasma glucose after ingestion of mixed meal
Time frame: During trial day, time 120-300 minutes
Butyrate
Plasma concentrations of butyrate
Time frame: During trial day, time 0-300 minutes
Subjective appetite - appetite questionaire
We will assess subjective appetite sensations with a recommended primary scale for self-reported appetite in healthy adults. The scale includes five questions addressing hunger, fullness, satiety, desire to eat and prospective consumption. The participants answer on a computer or tablet by sliding a button on a horizontal line (Visual Analog Scale) with left being eg. "Not hungry at all" to right "As hungry as I have ever felt".
Time frame: 0, 60, 120, 180, 240, 300 minutes
Caloric intake
Caloric intake (kcal) during ad libitum meal test
Time frame: Time 300 minutes
Gastric emptying assessed by acetaminophen
Plasma concentration of acetaminophen following oral acetaminophen intake
Time frame: From ingestion of mixed meal test with acetaminophen, time 120-240 minutes
GLP-1
Plasma concentrations of GLP-1
Time frame: During trial day, time 0-300 minutes
GIP
Plasma concentrations of GIP
Time frame: During trial day, time 0-300 minutes
LEAP2
Plasma concentrations of LEAP2
Time frame: During trial day, time 0-300 minutes
PYY
Plasma concentrations of PYY
Time frame: During trial day, time 0-300 minutes
Ghrelin
Plasma concentrations of ghrelin
Time frame: During trial day, time 0-300 minutes
Insulin
Plasma concentrations of insulin
Time frame: During trial day, time 0-300 minutes
C-peptide
Plasma concentrations of c-peptide
Time frame: During trial day, time 0-300 minutes
Glucagon
Plasma concentrations of glucagon
Time frame: During trial day, time 0-300 minutes
Cardiac function
Echocardiographic assessment of cardiac output, left ventricular ejection fraction, global longitudinal strain, tricuspid annular plane systolic excursion (TAPSE), systemic vascular resistance
Time frame: Time 0 and 90 minutes
β-hydroxybutyrate
Plasma concentrations of β-hydroxybutyrate
Time frame: During trial day, time 0-300 minutes
Lactate
Plasma concentrations of lactate
Time frame: During trial day, time 0-300 minutes
C-reactive protein (CRP)
Plasma concentrations of CRP
Time frame: On trial day, time 0 minutes
Tumor Necrosis Factor ⍺ (TNF-⍺)
Plasma concentrations of TNF-⍺
Time frame: On trial day, time 0 minutes
Interleukin 6 (IL-6)
Plasma concentrations of IL-6
Time frame: On trial day, time 0 minutes
Interleukin 10 (IL-10)
Plasma concentrations of IL-10
Time frame: On trial day, time 0 minutes
Lipopolysaccharide Binding Protein (LPB)
Plasma concentrations of LPB
Time frame: On trial day, time 0 minutes
Cortisol
Plasma concentration of cortisol
Time frame: On trial day, time 0 minutes
Triglyceride
Plasma concentrations of triglyceride
Time frame: During trial day, time 0-300 minutes
FFA
Plasma concentrations of free fatty acids
Time frame: During trial day, time 0-300 minutes
Energy expenditure
Indirect calorimetry
Time frame: After 60 and 150 minutes approximately
Sleep
Assessment of sleep duration and stages
Time frame: Three nights at the end of the 2 week period at home
Fecal butyrate
Fecal concentrations of butyrate
Time frame: Day 0, 7, 14 during the 2 week period
Microbiome composition
Analysis of microbiome composition and metagenomics performed on fecal samples
Time frame: Day 0, 7, 14 during the 2 week period
Plan to share: No — The corresponding author will make data available on reasonable request.
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 10 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tributyrin